The Scientist

» biotechnology and immunology

Most Recent

image: Report: Still Lots to Learn About GE Crops

Report: Still Lots to Learn About GE Crops

By | May 17, 2016

A National Academies–led analysis evaluates the impacts of genetically engineered crops—and calls for updated regulations.

1 Comment

image: Tasmanian Devil Antibodies Fight Cancer

Tasmanian Devil Antibodies Fight Cancer

By | May 9, 2016

The proteins could be the key to stopping the transmissible facial tumor disease that is threatening the species.

0 Comments

image: Breast Milk Primes Gut for Microbes

Breast Milk Primes Gut for Microbes

By | May 5, 2016

Maternal antibodies engender a receptive gut environment for beneficial bacteria in newborn mice.

2 Comments

image: Lu on Syn Bio

Lu on Syn Bio

By | May 1, 2016

MIT researcher and Scientist to Watch Timothy Lu talks about the value of cross-disciplinary approaches in bringing synthetic biology into the clinic.

0 Comments

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: First Data from Anti-Aging Gene Therapy

First Data from Anti-Aging Gene Therapy

By | April 25, 2016

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

8 Comments

image: Study: “Dirty” Mice More Humanlike

Study: “Dirty” Mice More Humanlike

By | April 21, 2016

Housing laboratory mice with those reared in a pet store makes the lab rodents’ immune systems more similar to those of people.

2 Comments

image: Theranos in Criminal Probe

Theranos in Criminal Probe

By | April 19, 2016

Federal officials are investigating whether the diagnostics company misled investors.

2 Comments

image: AACR Q&A: Elaine Mardis

AACR Q&A: Elaine Mardis

By | April 18, 2016

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

0 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. Mapping the Human Connectome
    Daily News Mapping the Human Connectome

    A new map of human cortex combines data from multiple imaging modalities and comprises 180 distinct regions.

  2. Will Organs-in-a-Dish Ever Replace Animal Models?
  3. Your Office Has a Distinct Microbiome
  4. Neurons Compete to Form Memories
RayBiotech